Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma.
Date
2018-01
Journal Title
Journal ISSN
Volume Title
Citation Stats
Abstract
Immune checkpoint inhibitors have improved patient survival outcomes in a variety of advanced malignancies. However, they can cause a number of immune-related adverse effects (irAEs) through lymphocyte dysregulation. Central nervous system (CNS) irAEs are rare, but as the number of indications for checkpoint inhibitors increases, there has been emergence of CNS immune-mediated disease among cancer patients. Given the relatively recent recognition of checkpoint inhibitor CNS irAEs, there is no standard treatment, and prognosis is variable. Therefore, there is a great need for further study of checkpoint inhibitor-induced CNS irAEs. Here, we present two unique cases of nivolumab-induced autoimmune encephalitis in patients with non-small cell lung cancer and review the available literature.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Shah, Suma, Anastasie Dunn-Pirio, Matthew Luedke, Joel Morgenlander, Mark Skeen and Christopher Eckstein (2018). Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma. Case reports in neurological medicine, 2018. p. 2548528. 10.1155/2018/2548528 Retrieved from https://hdl.handle.net/10161/17399.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.